• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconPharmaceutical Industry

Pharmaceutical Industry

Page 89 of 100
New Reasearch Shows That Aspirin May Cut Breast Cancer Risk
HealthThe world’s biggest clinical trial is for one of the cheapest drugs
By Claire GrodenOctober 22, 2015
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
FinanceForget the plunging stock price, here’s Valeant’s biggest problem
By Laura LorenzettiOctober 22, 2015
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
HealthShort-seller: Is Valeant the pharmaceutical Enron?
By Laura LorenzettiOctober 21, 2015
519891667
HealthDrug companies are paying huge sums to fast-track FDA approval
By Laura LorenzettiOctober 20, 2015
MSMB Capital Management CIO Martin Shkreli
LeadershipThe face of high drug prices is trolling Bernie Sanders on Twitter
By Michal AddadyOctober 19, 2015
Marco Rubio
LeadershipMarco Rubio calls out high drug prices
By Ben GeierOctober 19, 2015
Parkinson’s patients show improvement after taking cancer drug
HealthParkinson’s patients show improvement after taking cancer drug
By Claire ZillmanOctober 19, 2015
J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., waits for the start of their annual general meeting in Laval, Quebec
HealthValeant eases up on strategy to buy up ‘mispriced drugs’
By Laura LorenzettiOctober 19, 2015
J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., waits for the start of their annual general meeting in Laval, Quebec
HealthValeant beat expectations in 3Q thanks to U.S. skin business
By Reuters and Fortune EditorsOctober 19, 2015
Hillary Clinton in the first Democratic presidential debate in Las Vegas on Oct. 13
CommentaryClinton’s big pharma takedown plan has some serious issues
By Chris Ford and Bethany CiancioloOctober 16, 2015
Democratic Candidates Attend New Hampshire Democratic Party Convention
LeadershipBernie Sanders rejects drug price-raising CEO’s donation: ‘We don’t want his stinkin’ money’
By Michal AddadyOctober 16, 2015
CNBC NEWS-- Pictured: Jeb Bush, former Governor of Florida and 2016 presidential election candidate, in an interview at the Parlor City Pub and Eatery in Cedar Rapids, Iowa on September 22, 2015 -- (Photo by: Mary Stevens/CNBC/NBCU Photo Bank)
HealthJeb Bush’s health care plan would dismantle Obamacare
By Laura LorenzettiOctober 15, 2015
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
HealthValeant under federal investigation for how it prices drugs
By Laura LorenzettiOctober 15, 2015
Johnson & Johnson Products Ahead Of Earnings
HealthJohnson & Johnson struggles to boost drug sales even as profits gain
By Laura LorenzettiOctober 13, 2015
Eli Lilly & Co's Zyprexa schizophrenia drug is pictured in a
FinanceEli Lilly adds one more to roster of failed heart drugs, and it won’t be the last
By Laura LorenzettiOctober 12, 2015
1...
  • 87
  • 88
  • 89
  • 90
  • 91
...100
Most Popular
Economy
The U.S. government is spending $88 billion a month in interest on national debt—equal to spending on defense and education combinedplaceholder alt text
By Fortune EditorsApril 9, 2026
AI
A Meta employee created a dashboard so coworkers can compete to be the company's No. 1 AI token user—and Zuckerberg doesn't even rank in the top 250placeholder alt text
By Fortune EditorsApril 9, 2026
Investing
Mark Cuban admits he made a mistake letting go of the Mavericks: 'I don't regret selling. I regret who I sold to'placeholder alt text
By Fortune EditorsApril 9, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.